Abstract 1598P
Background
The importance of Hospice & Palliative care for patients with terminal cancer is well established. Although hospice use is increasing, the use of hospice services is still suboptimal. Previous studies reported that surgeons tend to underuse palliative care (PC) consultation. This study aimed to investigate potential variations in referral patterns to the PC team and differences in end-of-life care among specialized physicians in patients with terminal cancer.
Methods
A single-institution retrospective observational study of consecutive PC consultations within a National Cancer Institute-designated cancer center in 2020-2021 was conducted. We categorized specialized physicians into medical oncologists (MO) and non-medical oncologists (NMO), which include hematologists, gastroenterologists, surgical and radiation oncologists.
Results
We analyzed 1710 patients, 1130 were referred from MO and 580 from NMO. Patients in the NMO group had lower levels of prognostic awareness (PA) regarding their terminal cancer status compared to those in MO. 44.7 % of patients in the MO group and 16.2 % of patients in the NMO group had accurate PA (p<0.01). The median survival from a day of PC consultation was 40.7 days for all, 47.3 days for the MO group, and 28 days for NMO group (p = 0.00). The survival time after planning Advance Directives was 100 days for all, significantly longer in the MO group (131.2 vs. 54.9 days, p=0.00). The median time from notification of discontinuation of active cancer treatment to PC consultation was 40 days. The interval to PC consultation was significantly longer in patients referred from the NMO group (92.6 days in the NMO group vs. 13.5 days in the MO group, p=0.00). The rate of discharge to specialized inpatient hospice facilities or home hospice was higher in the MO group. However, the discharge rate to acute-stage hospital, ICU was higher in the NMO group.
Conclusions
There was significant variation in referral patterns to the PC team according to a division of physicians. NMO patients had a lower level of prognostic awareness (PA) compared to MO patients. Late referrals to the PC team were observed in the NMO group. This suggests a need for increased education and training in palliative care for the NMO.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05